Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 16Completed 15Terminated 7Not yet recruiting 7Active not recruiting 6Unknown 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 240Carcinoma, Renal Cell 75Urinary Bladder Neoplasms 56Kidney Neoplasms 32Breast Neoplasms 26Neoplasms 25Carcinoma, Transitional Cell 22Neoplasm Metastasis 21Carcinoma, Non-Small-Cell Lung 14Sarcoma 11Non-Muscle Invasive Bladder Neoplasms 11Lung Neoplasms 11Melanoma 10Wilms Tumor 8Testicular Neoplasms 8Colorectal Neoplasms 8Uterine Cervical Neoplasms 7Urologic Neoplasms 7Stomach Neoplasms 7Pancreatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Recurrence 6Ovarian Neoplasms 6Endometrial Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Prostatic Neoplasms, Castration-Resistant 5Neuroblastoma 5Esophageal Neoplasms 5

Interventions

pembrolizumab 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Clear-cell metastatic renal cell carcinoma × Genitourinary × Clear all
NCT06361810 2025-08-19

PSMA Therapy and Immunotherapy in Kidney Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Withdrawn
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡